Annals of Hematology

, Volume 86, Issue 7, pp 499–508 | Cite as

Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature

  • Jaspreet S. Grewal
  • Lauren B. Smith
  • Jerome D. WinegardenIII
  • John C. Krauss
  • Joseph A. Tworek
  • Bertram Schnitzer
Original Article


Anaplastic large cell lymphoma (ALCL) is an aggressive neoplasm of T- or null cell phenotype and is recognized as a distinct clinicopathologic subtype of non-Hodgkin lymphoma (NHL) in the revised World Health Organization (WHO) classification of hematopoietic neoplasms. It is rarely associated with leukemic phase. Most cases with leukemic involvement are the small cell variant of ALCL. These cases often lack the pleomorphism seen in the common variant of ALCL and may be misdiagnosed. We report a series of three patients who presented with leukemic phase ALCL. The patients included an 11-year-old boy, a 29-year-old man, and a 59-year-old woman. The clinical and pathologic features of these cases are reviewed. The patients in our case series with leukemic phase ALCL exhibited rare clinical features. The patients presented with massive extranodal disease involving cerebrospinal fluid (CSF), liver, spleen, lungs, and bone marrow. CSF involvement was documented morphologically as well as by flow cytometry in two patients. Two of the patients had small cell variant and the third patient had common type ALCL. The neoplastic cells in all three patients were ALK positive; however these patients died within months of diagnosis. Leukemic phase ALCL is rare, and behaves in an aggressive manner. Some, but not all, cases in the literature presenting with peripheral blood involvement had small cell variant ALCL, as seen in two of our cases. The leukemic phase of ALCL should be considered when a T-cell leukemia with unusual morphologic features is encountered.


Anaplastic large cell lymphoma Small cell variant Anaplastic lymphoma kinase ALK 


  1. 1.
    Drexler HG, Gignac SM, von Wasielewski R et al (2000) Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14:1533–1559PubMedCrossRefGoogle Scholar
  2. 2.
    Gudgin E, Rashbass J, Pulford KJ et al (2005) Primary and isolated anaplastic large cell lymphoma of the bone marrow. Leuk Lymphoma 46:461–463PubMedCrossRefGoogle Scholar
  3. 3.
    Kadin ME, Carpenter C (2003) Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 40:244–256PubMedCrossRefGoogle Scholar
  4. 4.
    Massimino M, Gasparini M, Giardini R (1995) Ki-1 (CD30) anaplastic large-cell lymphoma in children. Ann Oncol 6:915–920PubMedGoogle Scholar
  5. 5.
    Stein H, Foss HD, Durkop H et al (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681–3695PubMedGoogle Scholar
  6. 6.
    Weisenburger DD, Anderson JR, Diebold J et al (2001) Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin’s lymphoma classification project. Am J Hematol 67:172–178PubMedCrossRefGoogle Scholar
  7. 7.
    Wright D, McKeever P, Carter R (1997) Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children’s Cancer Study Group. J Clin Pathol 50:128–134PubMedGoogle Scholar
  8. 8.
    Stein H, Mason DY, Gerdes J et al (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848–858PubMedGoogle Scholar
  9. 9.
    Fischer P, Nacheva E, Mason DY et al (1988) A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin’s lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 72:234–240PubMedGoogle Scholar
  10. 10.
    Ladanyi M (1997) The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma. Cancer Surv 30:59–75PubMedGoogle Scholar
  11. 11.
    Le Beau MM, Bitter MA, Larson RA et al (1989) The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 3:866–870PubMedGoogle Scholar
  12. 12.
    Mason DY, Bastard C, Rimokh R et al (1990) CD30-positive large cell lymphomas (’Ki-1 lymphoma’) are associated with a chromosomal translocation involving 5q35. Br J Haematol 74:161–168PubMedGoogle Scholar
  13. 13.
    Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284PubMedCrossRefGoogle Scholar
  14. 14.
    Agnarsson BA, Kadin ME (1988) Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases. Am J Surg Pathol 12:264–274PubMedCrossRefGoogle Scholar
  15. 15.
    Benharroch D, Meguerian-Bedoyan Z, Lamant L et al (1998) ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91:2076–2084PubMedGoogle Scholar
  16. 16.
    Brugieres L, Deley MC, Pacquement H et al (1998) CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92:3591–3598PubMedGoogle Scholar
  17. 17.
    Falini B, Bigerna B, Fizzotti M et al (1998) ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol 153:875–886PubMedGoogle Scholar
  18. 18.
    Massimino M, Spreafico F, Luksch R et al (2001) Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL). Med Pediatr Oncol 37:97–102PubMedCrossRefGoogle Scholar
  19. 19.
    Mori T, Kiyokawa N, Shimada H et al (2003) Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development. Br J Haematol 121:94–96PubMedCrossRefGoogle Scholar
  20. 20.
    Nakamura S, Shiota M, Nakagawa A et al (1997) Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 21:1420–1432PubMedCrossRefGoogle Scholar
  21. 21.
    Pittaluga S, Wlodarska I, Pulford K et al (1997) The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 151:343–351PubMedGoogle Scholar
  22. 22.
    Pulford K, Roberton HM, Jones M (2005) Antibody techniques used in the study of anaplastic lymphoma kinase-positive ALCL. Methods Mol Med 115:271–294PubMedGoogle Scholar
  23. 23.
    Shiota M, Nakamura S, Ichinohasama R et al (1995) Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86:1954–1960PubMedGoogle Scholar
  24. 24.
    Falini B (2001) Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol 114:741–760PubMedCrossRefGoogle Scholar
  25. 25.
    Kadin ME (1997) Anaplastic large cell lymphoma and its morphological variants. Cancer Surv 30:77–86PubMedGoogle Scholar
  26. 26.
    Kadin ME (1994) Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. Ann Oncol 5(Suppl 1):25–30PubMedGoogle Scholar
  27. 27.
    Greer JP, Kinney MC, Collins RD et al (1991) Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 9:539–547PubMedGoogle Scholar
  28. 28.
    Kinney MC, Collins RD, Greer JP et al (1993) A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 17:859–868PubMedCrossRefGoogle Scholar
  29. 29.
    Kinney MC, Greer JP, Glick AD et al (1991) Anaplastic large-cell Ki-1 malignant lymphomas. Recognition, biological and clinical implications. Pathol Annu 26(Pt 1):1–24PubMedGoogle Scholar
  30. 30.
    Rubie H, Gladieff L, Robert A et al (1994) Childhood anaplastic large cell lymphoma Ki-1/CD30: clinicopathologic features of 19 cases. Med Pediatr Oncol 22:155–161PubMedCrossRefGoogle Scholar
  31. 31.
    Anderson MM, Ross CW, Singleton TP et al (1996) Ki-1 anaplastic large cell lymphoma with a prominent leukemic phase. Hum Pathol 27:1093–1095PubMedCrossRefGoogle Scholar
  32. 32.
    Kinney MC, Kadin ME (1999) The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am J Clin Pathol 111:S56–S67PubMedGoogle Scholar
  33. 33.
    Morris SW, Xue L, Ma Z et al (2001) Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin’s lymphoma. Br J Haematol 113:275–295PubMedCrossRefGoogle Scholar
  34. 34.
    Cheuk W, Chan JK (2001) Timely topic: anaplastic lymphoma kinase (ALK) spreads its influence. Pathology 33:7–12PubMedCrossRefGoogle Scholar
  35. 35.
    Gascoyne RD, Aoun P, Wu D et al (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921PubMedGoogle Scholar
  36. 36.
    Herbst H, Anagnostopoulos J, Heinze B et al (1995) ALK gene products in anaplastic large cell lymphomas and Hodgkin’s disease. Blood 86:1694–1700PubMedGoogle Scholar
  37. 37.
    Pulford K, Falini B, Cordell J et al (1999) Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma. Am J Pathol 154:1657–1663PubMedGoogle Scholar
  38. 38.
    Tai YC, Kim LH, Peh SC (2003) Common ALK gene rearrangement in Asian CD30+ anaplastic large cell lymphoma: an immunohistochemical and fluorescence in situ hybridisation (FISH) study on paraffin-embedded tissue. Pathology 35:436–443PubMedCrossRefGoogle Scholar
  39. 39.
    Vecchi V, Burnelli R, Pileri S et al (1993) Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. Med Pediatr Oncol 21:402–410PubMedCrossRefGoogle Scholar
  40. 40.
    Bischof D, Pulford K, Mason DY et al (1997) Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17:2312–2325PubMedGoogle Scholar
  41. 41.
    Hubinger G, Scheffrahn I, Muller E et al (1999) The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. Exp Hematol 27:1796–1805PubMedCrossRefGoogle Scholar
  42. 42.
    Kaplinsky C, Toren A, Neumann Y et al (1997) Central nervous system involvement at diagnosis in a case of pediatric CD30+ anaplastic large cell lymphoma. Med Pediatr Oncol 28:132–135PubMedCrossRefGoogle Scholar
  43. 43.
    Seidemann K, Tiemann M, Schrappe M et al (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin–Frankfurt–Munster Group Trial NHL-BFM 90. Blood 97:3699–3706PubMedCrossRefGoogle Scholar
  44. 44.
    ten Berge RL, Oudejans JJ, Ossenkoppele GJ et al (2000) ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 53:445–450PubMedCrossRefGoogle Scholar
  45. 45.
    Williams DM, Hobson R, Imeson J et al (2002) Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol 117:812–820PubMedCrossRefGoogle Scholar
  46. 46.
    Bayle C, Charpentier A, Duchayne E et al (1999) Leukaemic presentation of small cell variant anaplastic large cell lymphoma: report of four cases. Br J Haematol 104:680–688PubMedCrossRefGoogle Scholar
  47. 47.
    Fraga M, Brousset P, Schlaifer D et al (1995) Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 103:82–89PubMedGoogle Scholar
  48. 48.
    Abdulkader I, Cameselle-Teijeiro J, Fraga M et al (1999) Primary anaplastic large cell lymphoma of the central nervous system. Hum Pathol 30:978–981PubMedCrossRefGoogle Scholar
  49. 49.
    Armstrong G, Szallasi A, Biegel JA et al (2005) Early molecular detection of central nervous system relapse in a child with systemic anaplastic large cell lymphoma: case report and review of the literature. Pediatr Blood Cancer 44:400–406PubMedCrossRefGoogle Scholar
  50. 50.
    Buxton N, Punt J, Hewitt M (1998) Primary Ki-1-positive T-cell lymphoma of the brain in a child. Pediatr Neurosurg 29:250–252PubMedCrossRefGoogle Scholar
  51. 51.
    George DH, Scheithauer BW, Aker FV et al (2003) Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. Am J Surg Pathol 27:487–493PubMedCrossRefGoogle Scholar
  52. 52.
    Goldbrunner R, Warmuth-Metz M, Tonn JC et al (1996) Primary Ki-1-positive T-cell lymphoma of the brain–an aggressive subtype of lymphoma: case report and review of the literature. Surg Neurol 46:37–41PubMedCrossRefGoogle Scholar
  53. 53.
    Havlioglu N, Manepalli A, Galindo L et al (1995) Primary Ki-1 (anaplastic large cell) lymphoma of the brain and spinal cord. Am J Clin Pathol 103:496–499PubMedGoogle Scholar
  54. 54.
    Kawamura T, Inamura T, Ikezaki K et al (2001) Primary Ki-1 lymphoma in the central nervous system. J Clin Neurosci 8:574–577PubMedCrossRefGoogle Scholar
  55. 55.
    Lin CN, Hou CC, Hwang WS et al (2003) Anaplastic large cell lymphoma—a rare disorder in southern Taiwan. Leuk Lymphoma 44:1727–1731PubMedCrossRefGoogle Scholar
  56. 56.
    Mori T, Sugita K, Kimura K et al (2003) Isolated central nervous system (CNS) relapse in a case of childhood systemic anaplastic large cell lymphoma without initial CNS involvement. J Pediatr Hematol Oncol 25:975–977PubMedCrossRefGoogle Scholar
  57. 57.
    Ponzoni M, Terreni MR, Ciceri F et al (2002) Primary brain CD30+ ALK1+ anaplastic large cell lymphoma (‘ALKoma’): the first case with a combination of ‘not common’ variants. Ann Oncol 13:1827–1832PubMedCrossRefGoogle Scholar
  58. 58.
    Reiter A, Schrappe M, Tiemann M et al (1994) Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin–Frankfurt–Munster group studies. J Clin Oncol 12:899–908PubMedGoogle Scholar
  59. 59.
    Rupani A, Modi C, Desai S et al (2005) Primary anaplastic large cell lymphoma of central nervous system—a case report. J Postgrad Med 51:326–327PubMedGoogle Scholar
  60. 60.
    Awaya N, Mori S, Takeuchi H et al (2002) CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma. Am J Hematol 69:200–204PubMedCrossRefGoogle Scholar
  61. 61.
    Hodges KB, Collins RD, Greer JP et al (1999) Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: pathologic and clinical features. Am J Surg Pathol 23:49–58PubMedCrossRefGoogle Scholar
  62. 62.
    Kong SY, Cho HJ, Suk JH et al (2004) A novel complex t(2;5;13)(p23;q35;q14) in small cell variant type anaplastic large cell lymphoma with peripheral involvement. Cancer Genet Cytogenet 154:183–185PubMedCrossRefGoogle Scholar
  63. 63.
    Lesesve JF, Buisine J, Gregoire MJ et al (2000) Leukaemic small cell variant anaplastic large cell lymphoma during pregnancy. Clin Lab Haematol 22:297–301PubMedCrossRefGoogle Scholar
  64. 64.
    Onciu M, Behm FG, Raimondi SC et al (2003) ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis. Report of three cases and review of the literature. Am J Clin Pathol 120:617–625PubMedCrossRefGoogle Scholar
  65. 65.
    Toren A, Neumann Y, Rosner E et al (1996) Pediatric small cell variant of Ki-1 (CD30) + T-cell lymphoma with germ-line configuration of the T-cell receptor gene. Acta Oncol 35:243–245PubMedGoogle Scholar
  66. 66.
    Villamor N, Rozman M, Esteve J et al (1999) Anaplastic large-cell lymphoma with rapid evolution to leukemic phase. Ann Hematol 78:478–482PubMedCrossRefGoogle Scholar
  67. 67.
    Escalon MP, Liu NS, Yang Y et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103:2091–2098PubMedCrossRefGoogle Scholar
  68. 68.
    Murphy SB (1994) Pediatric lymphomas: recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood. Ann Oncol 5(Suppl 1):31–33PubMedGoogle Scholar
  69. 69.
    Rosolen A, Pillon M, Garaventa A et al (2005) Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 104:2133–2140PubMedCrossRefGoogle Scholar
  70. 70.
    Sonnen R, Schmidt WP, Muller-Hermelink HK et al (2005) The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 129:366–372PubMedCrossRefGoogle Scholar
  71. 71.
    ten Berge RL, de Bruin PC, Oudejans JJ et al (2003) ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43:462–469PubMedCrossRefGoogle Scholar
  72. 72.
    Bakshi NA, Ross CW, Finn WG et al (2006) ALK-positive anaplastic large cell lymphoma with primary bone involvement in children. Am J Clin Pathol 125:57–63PubMedCrossRefGoogle Scholar
  73. 73.
    Ansell SM, Habermann TM, Kurtin PJ et al (1997) Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 15:2296–2301PubMedGoogle Scholar
  74. 74.
    Pulford K, Morris SW, Turturro F (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199:330–358PubMedCrossRefGoogle Scholar
  75. 75.
    Suzuki R, Kagami Y, Takeuchi K et al (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993–3000PubMedGoogle Scholar
  76. 76.
    ten Berge RL, Dukers DF, Oudejans JJ et al (1999) Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 93:2688–2696PubMedGoogle Scholar
  77. 77.
    Brugieres L, Quartier P, Le Deley MC et al (2000) Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology. Ann Oncol 11:53–58PubMedCrossRefGoogle Scholar
  78. 78.
    Deconinck E, Lamy T, Foussard C et al (2000) Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 109:736–742PubMedCrossRefGoogle Scholar
  79. 79.
    Ait-Tahar K, Cerundolo V, Banham AH et al (2006) B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 118:688–695PubMedCrossRefGoogle Scholar
  80. 80.
    Borisch B, Yerly S, Cerato C et al (2003) ALK-positive anaplastic large-cell lymphoma: strong T and B anti-tumour responses may cause hypocellular aspects of lymph nodes mimicking inflammatory lesions. Eur J Haematol 71:243–249PubMedCrossRefGoogle Scholar
  81. 81.
    Cussac D, Greenland C, Roche S et al (2004) Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103:1464–1471PubMedCrossRefGoogle Scholar
  82. 82.
    Ergin M, Denning MF, Izban KF et al (2001) Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp Hematol 29:1082–1090PubMedCrossRefGoogle Scholar
  83. 83.
    Falini B, Pileri S, Pizzolo G et al (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1–14PubMedGoogle Scholar
  84. 84.
    Hatton C, Roberton H, Banham AH et al (2002) Persistence of antibody response to ALK proteins in patients with ALK-lymphoma. Annals of Oncology 13:46Google Scholar
  85. 85.
    Koon HB, Junghans RP (2000) Anti-CD30 antibody-based therapy. Curr Opin Oncol 12:588–593PubMedCrossRefGoogle Scholar
  86. 86.
    Passoni L, Gambacorti-Passerini C (2003) ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymphoma 44:1675–1681PubMedCrossRefGoogle Scholar
  87. 87.
    Pulford K, Falini B, Banham AH et al (2000) Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 96:1605–1607PubMedGoogle Scholar
  88. 88.
    Sforzini S, Bolognesi A, Meazza R et al (1995) Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies. Br J Haematol 90:572–577PubMedGoogle Scholar
  89. 89.
    Tazzari PL, Bolognesi A, de Totero D et al (1992) Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin’s disease and CD30+ lymphoma: in vitro evaluation. Br J Haematol 81:203–211PubMedGoogle Scholar
  90. 90.
    Tazzari PL, de Totero D, Bolognesi A et al (1999) An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins. Haematologica 84:988–995PubMedGoogle Scholar
  91. 91.
    Terenzi A, Bolognesi A, Pasqualucci L et al (1996) Anti-CD30(BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Br J Haematol 92:872–879PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Jaspreet S. Grewal
    • 1
  • Lauren B. Smith
    • 2
  • Jerome D. WinegardenIII
    • 3
  • John C. Krauss
    • 3
  • Joseph A. Tworek
    • 4
  • Bertram Schnitzer
    • 2
  1. 1.Department of Internal Medicine, Reichert Health CenterSt. Joseph Mercy HospitalAnn ArborUSA
  2. 2.Department of PathologyUniversity of Michigan Medical CenterAnn ArborUSA
  3. 3.Ann Arbor Hematology/Oncology AssociatesSt. Joseph Mercy HospitalAnn ArborUSA
  4. 4.Department of PathologySt. Joseph Mercy HospitalAnn ArborUSA

Personalised recommendations